The round was led by the Dementia Discovery Fund (DDF), making its first investment from its latest fund – the Dementia Discovery Fund 2 (DDF-2)
Violet Therapeutics has announced the successful closing of a $10.6 million seed funding round.
The round was led by the Dementia Discovery Fund (DDF), making its first investment from its latest fund – the Dementia Discovery Fund 2 (DDF-2) – and co-led by UTEC (University of Tokyo Edge Capital Partners), and was joined by founding investor Mass General Brigham Ventures (MGBV) and Ono Venture Investment.
Violet was founded in 2021 by Mass General Brigham Ventures in collaboration with entrepreneurs and scientists from Brigham and Women’s Hospital including Dr Francisco J. Quintana, around novel neuroscience targets and multiple first-in-class target discovery platforms to identify, map and mine the cellular connectome at scale.
One of Violet’s discovery platforms, RABID-Seq, uses barcoded viral tracing to provide insights into cell–cell interactions at single-cell resolution. The scientific basis of this approach was published in Science magazine by Dr. Quintana and co-authors in 2021.
Violet is currently advancing a lead and first-of-its-kind program targeting neuroinflammation, which is being investigated for multiple neurodegenerative indications, including Alzheimer’s disease.
Jonathan Behr, PhD, Partner at the DDF, said: “The investment in Violet Therapeutics marks the first from our new fund generation, DDF-2. Finding effective treatments for dementia remains one of the greatest unmet medical challenges. We are impressed with the innovative approach that Violet has developed as it takes on this challenge, and are proud to support the company as it seeks to identify and develop effective therapeutics for diseases including dementias such as Alzheimer’s disease.”
Atsushi Usami, PhD, Partner and Board Director at the UTEC, added: “It is a great privilege to collaborate with Violet, a company dedicated to developing innovative solutions for drug discovery, particularly for diseases like neurodegenerative conditions with significant unmet medical needs. We firmly believe that Violet's groundbreaking technologies will facilitate the exploration of new drugs by identifying novel target molecules and mechanisms that have yet to be discovered.’’
In connection with the financing, Jonathan Behr and Atsushi Usami have joined Violet’s Board of Directors along with existing investor director, Meredith Fisher at Mass General Brigham Ventures.